Emerging Somatic Treatments and Research Directions in Treatment-Resistant Depression
Carlos A. Zarate, MD
Chief Experimental Therapeutics of the Mood and Anxiety Disorders Program, National Institute of Mental Health; Clinical Professor of Psychiatry and Behavioral Sciences, George Washington University
Disclosures: Discussion of off-label uses (using products for a purpose other than that for which it was approved by the Food and Drug Administration, or FDA) will occur during this presentation. The speaker has no conflicts of interest to disclose. The activity planners have no conflicts of interest to disclose.
Upon completion of this presentation, the participant will be able to:
1. Understand the reasons for treatment-resistance in mood disorders.
Recognize strategies for the pharmacological management of treatment-resistant depression.
2. Become familiar with drug discovery and development in treatment-resistant depression.
Continuing Nursing Education
1.5 contact hours. * In order to receive contact hours, you must: Listen to the entire session, complete an evaluation, and earn a passing score on the post test before the expiration date.You will have 5 tries to earn a score of 80% or better on the post test. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. We cannot award credit unless all steps are completed.
The content of this CNE activity pertains to pharmacology. Because states' requirements may vary, contact your Board of Nursing for more information.
The American Psychiatric Nurses Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
June 26, 2010
Hyatt Regency Reston
Release Date: August 23, 2010
The contact hours for this session expire: March 14, 2014